Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Capone

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Journal of Clinical Immunology|July 9, 2022
Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring HospitalizationGiulia Lamacchia, Alessio Mazzoni, Michele Spinicci, et al.
Immunology Letters|June 21, 2024
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipientsManuela Capone, Anna Vanni, Lorenzo Salvati, et al.
Leukemia|August 21, 2020
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational studyAlessandro M Vannucchi, Benedetta Sordi, Alessandro Morettini, et al.
The Journal of Clinical Investigation|May 29, 2020
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependentAlessio Mazzoni, Lorenzo Salvati, Laura Maggi, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Journal of Clinical Immunology|July 9, 2022
Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring HospitalizationGiulia Lamacchia, Alessio Mazzoni, Michele Spinicci, et al.
Immunology Letters|June 21, 2024
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipientsManuela Capone, Anna Vanni, Lorenzo Salvati, et al.
Leukemia|August 21, 2020
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational studyAlessandro M Vannucchi, Benedetta Sordi, Alessandro Morettini, et al.
The Journal of Clinical Investigation|May 29, 2020
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependentAlessio Mazzoni, Lorenzo Salvati, Laura Maggi, et al.
Pageof 7